Earnings

Fate Therapeutics Q3 EPS $(0.25) Beats $(0.27) Estimate

Nov 5, 2026 · 07:37 AM ET· updated 2h ago

Fate Therapeutics (NASDAQ:FATE) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.27) by 7.41 percent. This is a 7.41 percent increase over losses of $(0.27) per share from

Why It Matters

Fate Therapeutics lost less money than Wall Street thought it would. When a company bleeds money slower than expected, it hints the team is spending wisely.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

FATE1.93

-0.16 (-7.66%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.